Codex DNA
Latest round
- Series A
Last raised
- Dec 2019
Total raised
- $25M
Investors
- 3
About Codex DNA
, formerly SGI-DNA, Inc. operates as a provider of genomic tools that help scientists to discover, design, and build solutions for basic research, biomedical and industrial applications. The company was founded by Dan Gibson and Todd Nelson. In September 2019, the company also commercialized its synthetic biology solution, which incorporates the BioXp 3250 system. As of June 2021, the company had 101 employees and has installed roughly 160 BioXp systems across the world. In June 2021, Codex DNA, Inc.7 million shares at USD 16 per share. It trades on Nasdaq under the ticker symbol DNAY. The company offers BioXp, a DNA printer that improves the workflows for protein production and cell engineering, and Gibson Assembly Reagents, a cloning procedure that allows the joining of two or more fragments.
Who invested in Codex DNA
3 investors across 2 rounds
See all investors in Codex DNA
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Codex DNA
Who invested in Codex DNA?
Codex DNA has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Codex DNA raised?
Codex DNA has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Codex DNA last raise money?
Codex DNA's most recent round on record is a Series A, in Dec 2019.
What does Codex DNA do?
Codex DNA is a biotechnology company.
Where is Codex DNA headquartered?
Codex DNA is headquartered in San Diego, US.
Which VCs invest in companies like Codex DNA?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Codex DNA's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Codex DNA? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.